INVO Fertility, Inc. reported its financial results for the quarter ending June 30, 2025, revealing a total revenue of approximately $1.86 million, a slight increase from $1.84 million in the same period last year. The company's clinic revenue rose to $1.83 million, compared to $1.81 million in the prior year, while product revenue also saw a modest increase. However, the company incurred a net loss of approximately $5.28 million for the quarter, significantly higher than the loss of $2.25 million reported in the same quarter of 2024. For the first half of 2025, total revenue reached $3.50 million, up from $3.41 million in the first half of 2024, but the net loss ballooned to $22.69 million, compared to $3.84 million in the previous year.
The financial performance reflects several strategic developments, including the divestiture of an 80.1% stake in NAYA Therapeutics in June 2025, which allowed INVO to refocus on its core fertility business. The company also completed a public offering in January 2025, raising approximately $8.7 million in net proceeds, which was partially used to redeem preferred stock and repay debt. Additionally, INVO has been actively pursuing the acquisition of profitable IVF clinics to enhance its operational scale and revenue generation capabilities.
Operationally, INVO Fertility has two operational INVO Centers and one IVF clinic in the United States. The company reported an increase in customer engagement, with clinic revenue contributing significantly to its overall performance. However, the company also faced challenges, including a $1.4 million impairment loss related to a noncompetition agreement and a loss of $1.53 million from the disposal of NTI. The total liabilities decreased to approximately $16.69 million as of June 30, 2025, down from $26.24 million at the end of 2024, primarily due to the reduction in convertible notes payable.
Looking ahead, INVO Fertility aims to continue expanding its clinic operations and enhancing the adoption of its INVOcell technology. The company plans to open additional INVO Centers and acquire more established IVF clinics to drive growth. However, it acknowledges the need for further capital to support its operations and strategic initiatives, as it has been reliant on debt and equity financing to meet its liquidity needs. The company’s management has expressed concerns regarding its ability to continue as a going concern, given the significant operating losses and the need for additional funding in the near future.
About INVO Fertility, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.